• 1
    Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 3246.
  • 2
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 3
    Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, Daynes RA. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 2106.
  • 4
    Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GH, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 199700.
  • 5
    Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoyaerts MF, Arnout J. Thrombogenicity of β2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 15762.
  • 6
    Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: S1149.
  • 7
    Pierangeli SS, Girardi G, Vega-Ostertag ME, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 21204.
  • 8
    Simantov E, LaSala J, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 22119.
  • 9
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL. Endothelial cell target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-β2glycoprotein I and induce endothelial cell activation. Arthritis Rheum 1997; 40: 55161.
  • 10
    Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu X, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163: 29227.
  • 11
    Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris EN, Chen PP. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 38895.
  • 12
    Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 24550.
  • 13
    Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002; 1: 8438.
  • 14
    Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, Hughes GR, Velasco F. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 83441.
  • 15
    Zhou H, Woldberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 23538.
  • 16
    Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 154554.
  • 17
    Vega-Ostertag ME, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50: 29119.
  • 18
    Bohgaki M, Atsumi T, Yamashita Y, Yasuda Y, Sakai Y, Furusaki A, Bohgaki T, Amengual O, Amasaki Y, Koike T. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2glycoprotein I antibodies. Int Immunol 2004; 16: 163241.
  • 19
    López-Pedrera C, Buendia P, Cuadrado MJ, Sindones E, Aguirre MA, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M, Velasco F. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 30111.
  • 20
    Bradford MM. A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 24854.
  • 21
    Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 18.
  • 22
    Palomo I, Alarcon M, Sepulveda C, Pereira J, Espinola R, Pierangeli S. Prevalence of antiphospholipid antibody tests and diagnosis of the antiphospholipid syndrome. J Clin Lab Anal 2003; 17: 20915.
  • 23
    Colden-Stanfield M, Gallin E. Modulation of K+ currents in monocytes by VCAM-1 and E-selectin on activated human endothelium. Am J Physiol 1998; 275: C26777.
  • 24
    Yan WY, Zhao K, JIang Y, Huang Q, Wang J, Kan W, Wang S. Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide. Shock 2002; 17: 4338.
  • 25
    Campbell A, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the Antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 539534.
  • 26
    Smyth SS, Reis ED, Väänänen H, Zhang W, Coller BS. Variable protection of β3-integrin–deficient mice from thrombosis initiated by different mechanisms. Blood 2001; 98: 105562.
  • 27
    Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 1928.
  • 28
    Ferrara DE, Weiss D, Carnell PH, Vito RP, Vega D, Gao X, Nie S, Taylor WR. Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy. Am J Physiol Regulatory Integrative Comp Physiol 2005; 290: 11423.
  • 29
    Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, Durand JM, Harle JR, Bongrand P, Piette JC. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 5564.
  • 30
    Williams FMK, Parmar K, Hughes GRV, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. J Thromb Haemost 2000; 84: 7426.
  • 31
    Dumas J, Smith RA, Lowinger TB. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Devel 2004; 7: 60016.
  • 32
    Davies SP, Reddy H, Caivano M, Cohen Phillip. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95105.
  • 33
    Adams JL, Badger AM, Kumar S, Lee JC. P38 MAP kinase: molecular target for the inhibition of proinflammatory cytokines. Prog Med Chem 2001; 38: 160.
  • 34
    Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAPK kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185201.